Ben Hargreaves looks at why insulin’s price is so controversial and whether ... The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk ...

The rising price of insulin has become ... Biosimilar insulin is also on its way, which could further erode potential sales. By comparison, a new product in Lilly’s diabetes portfolio, Mounjaro ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

another patient at Erie Health who uses Lantus, an insulin pen. Last fall, after the 340B discount changed, she was quoted $490 at her pharmacy — the retail price for a box of insulin pens.

He added his office’s goal is to make sure insulin prices do not increase after these five years. During the press conference, Ellison said diabetic patients were paying about $6,000 a year on ...

Ellison accused Novo Nordisk, Eli Lilly and Sanofi of inflating patients' out-of-pocket costs for insulin based on the wholesale acquisition cost, or list price, of the drug. The drugmakers were ...

Columbus joined a slough of cities, states and counties in suing drug companies and pharmacy benefit managers who they say artificially raised insulin prices for decades and profited from it ...

As far as immediate price reductions, the IRA also guarantees that many Medicare beneficiaries will pay no more than $35 out-of-pocket for insulin. This price cap is not only a practical win for ...

One order he issued, which rescinded President Joe Biden’s 2022 “Lowering Prescription Drug Costs for Americans” executive order, has been misinterpreted, prompting social media users to claim falsely ...

The message warning about insulin manufacturers announcing 2,000%-3,000% price increases after President Donald Trump rescinded a Joe Biden executive order originated as satire. This article was ...

Columbus City Attorney Zach Klein announced that the city has filed a lawsuit against several drug companies and pharmacy benefit managers (PBMs) for allegedly inflating insulin prices for decades ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report. GoodRx analyzed the ...